Questões de Inglês - Pronomes | Pronouns para Concurso
Foram encontradas 490 questões
Ano: 2023
Banca:
OBJETIVA
Órgão:
Prefeitura de Pinto Bandeira - RS
Prova:
OBJETIVA - 2023 - Prefeitura de Pinto Bandeira - RS - Professor (Letras/Inglês) |
Q2243146
Inglês
Maya Angelou, known in literature for her
autobiographical works, is the author of:
Ano: 2003
Banca:
FCC
Órgão:
CVM
Prova:
FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242137
Inglês
Texto associado
The hard cell
The hard cell
Thanks to politics, stem cell research in the United States is
suffering. But not so in Sweden, which is poised to capture what
could be the biggest new market to hit biotech in a decade.
By Stephan Herrera
February 13, 2003
New York, January 1, 2006:
Sweden announces that one of its biotechnology companies is the first in
the world to enter clinical trials with a new drug that could cure
Alzheimer's disease. Four years ago this type of research was all but
stopped in the United States by political and ethical questions − which is ...61... Sweden now seems in the best position to capture a $25 billion
market.
Any day now, the U.S. Congress is expected to pass a
sweeping new law that could dramatically inhibit researchers from working with stem cells taken from human embryos. Such
cells, which can be used to grow a whole host of new cells and
organs, could fundamentally change the way we treat heretofore
intractable maladies like Alzheimer's disease, Parkinson's
disease, cancer, stroke, liver failure, and heart disease. The only
problem is that these cells by definition are derived from human
embryos, many of which are cloned or come from unused
fetuses collected at fertility clinics. The argument, from a certain
segment of the American political spectrum, is that ....62... methods are morally wrong. They are ....63... a form of abortion or
an activity that could eventually lead to human cloning.
Those working in stem cell research say the short-term
effect of the legislation will be to further chill all forms of scientific
inquiry and commercialization efforts in the field. Entrepreneurs
and investors are already eschewing such research − in large
part because of the additional uncertainty and risk that politics
introduce.
Of the nearly 50 private stem cell companies in the
United States, only a handful are still viable. Meanwhile, across
the Atlantic, Sweden has avoided many of the political and
ethical quagmires surrounding this type of research. It currently
has 40 private stem cell companies, a number that's growing.
Sweden's leading research universities have 32 percent of the
world's stem cell inventory, close on the heels of the United
States' 35 percent.
Sweden, say analysts, is now in the best position to
capture a worldwide market for drugs based on stem cell
therapies that could grow to $25 billion in the next three to five
years − nearly equal to the whole biotech industry at present.
This estimate doesn't even address the market for stem cells
capable of repairing damaged vital organs like the brain, heart,
and kidneys. If the United States offers an object lesson of what
can happen when scientific inquiry and investment capital fall victim to politics, Sweden and its leading stem cell startup,
NeuroNova, offer the opposite example. How odd that the
United States, which for generations has been the envy of the
world for its progressive views of science and commercialization,
should now have a biomedical climate chillier than a Swedish
winter.
One company feeling a lot of pain is StemCells, which at
first glance seems to have it all: founding scientists include
Stanford's Dr. Weissman and Fred Gage of the Salk Institute in
La Jolla, California. An equally well-regarded expert in the
treatment of Alzheimer's, Dr. Gage spent five years in Sweden
as a researcher and now sits on a national committee on stem
cell research there. The firm's chairman is Roger Perlmutter,
Amgen's head of research.
Yet over the past two years, none of management's
efforts to help investors and even critics reconsider the stem cell
field have worked. At press time, the stock was thinly traded and
sitting in the neighborhood of 50 cents. With less than $15
million in cash, the company likely won't exist at this time next
year. (CEO Martin McGlynn, who joined the firm in January
2001, would not talk to Red Herring, despite repeated efforts.)
Some observers on Wall Street are asking, If StemCells
can't make it, who can? Geron, the only other publicly held stem
cell firm to speak of, is in a fix, too. The company's stock price is
also moribund, at $3.85 per share. Thanks to some capital
infusions a few years ago, when money came easy, Geron still
has $40 million on hand, but by the end of next year, that too will
likely be gone. Once a media darling, Geron focuses on
diagnostic tests and drugs derived from stem cells, a strategy
that's not going well. For the nine months ended last September,
revenue fell 68 percent to $955,000 and net loss widened 18
percent to $26.7 million. The company's financials were also hit
hard after it terminated an agreement with Pharmacia and acquired research technology from Lynx Therapeutics, which
Geron bought in a desperate attempt to be seen as something
more than just a stem cell company.
The situation is quite different, however, for Sweden's
NeuroNova, which has 30 academic partners and a staff of 20.
NeuroNova is working on ways to inject stem cells into the
human brain to trigger a process called neurogenesis (the
growth of new neural cells), which could combat diseases like
Parkinson's, Alzheimer's, and even schizophrenia.
If NeuroNova is the first to develop a drug capable of
treating one of several central nervous system disorders − by far
the most lucrative after heart disease products − it will have
done so not because it raised more money or got more media
buzz than the rest. It will have succeeded because the science
is solid, and academe, government, and the investment
community are supportive. Meanwhile, the United States will
look on with envy and wonder how it, a country known for its
entrepreneurial innovation, ever got so short-sighted.
(Adapted from
http://www.redherring.com/investor/2003/02/biotech021303.html)
Instruções: Para responder a questão, assinale, na folha de respostas, a letra correspondente a alternativa que preenche corretamente a lacuna do texto apresentado.
Ano: 2003
Banca:
FCC
Órgão:
CVM
Prova:
FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242131
Inglês
Texto associado
From the IPO to the First Trade: Is Underpricing Related to the
Trading Mechanism?
Sonia Falconieri, Albert Murphy and Daniel Weaver
As documented by a vast empirical literature, IPOs are
characterized by underpricing. Most of the theoretical literature
has linked the size of underpricing to the IPO procedure used on
the primary market. In this paper, by using a matched sample of
NYSE and Nasdaq IPOs, we show that the size of underpricing
also depends on the trading method used in the IPO
aftermarket.
There are two major methods of opening trading of initial
public offerings (IPOs) in the U.S. The NYSE is an order-driven
market ....56... a call auction allows supply and demand to be
aggregated (at one location) prior to the start of trading. .....57.... ,
Nasdaq is a quote-driven market. Dealers can only specify their
best quotes, and participants have KK
58 idea of supply and
demand away from the inside quotes.
We propose a new proxy for ex ante uncertainty of firm
value and test it. Our results show that there is a larger level of
uncertainty at the beginning of trading on Nasdaq than on the
NYSE. This in turn is associated with larger levels of
underpricing for Nasdaq IPOs. We suggest that this may be due
to the different informational efficiency of the two trading
systems.
(http://www.nyse.com/marketinfo/p1020656068262.html?displayPage=%
2Fmarketinfo%2Fmarketinfo.html)
Instruções: Para responder à questão,
assinale, na folha de respostas, a letra correspondente à alternativa que preenche corretamente a lacuna do texto apresentado.
Ano: 2023
Banca:
FURB
Órgão:
Prefeitura de Doutor Pedrinho - SC
Prova:
FURB - 2023 - Prefeitura de Doutor Pedrinho - SC - Professor (Inglês) |
Q2231441
Inglês
Texto associado
(§1º)Budelli Island is part of the La Maddalena
Archipelago and is home to Spiaggia Rosa - a stretch of
pink sand that's been protected by the Italian government
since 1992.
(§2º)The pink shade is caused by the crushed shells of a
micro-organism mixing with the sand when it dies. But
when the beach started to lose its rose-tinted hue
because of over-tourism, visitors were banned in a bit to
protect the pink sand.
(§3º)The colour has since returned but a new wave of
unauthorised daytrippers are threatening the pink shores.
While it is strictly forbidden to step foot on the beach,
holidaymakers are able to admire the pink sand from the
safety of a boat. But according to one expert, some
holidaymakers are flouting the ban.
(§4º)In an article in the Times, Fabrizio Fonnesu, director
of the Maddalena archipelago national park said: "The
beach is again in danger as people arrive by boat,
clamber up the beach, then post photos, which allow us
to fine them up to 500 euros (£430)."
(§5º)Tourists who've attempted to take Sardinia's pink
sand away as a souvenir can up fined up to 3,500 euros (£3,007). And according to the Guardian, a couple were
fined 1,000 euros (£860) in 2001 after they were caught
filling a plastic bottle with sand.
(§6º)Brits who want to visit the island will need to book
themself onto a private boat tour or a ferry service to
glimpse this secluded spot from afar. Other beaches on
the island have also brought in measures to minimise the
impact of tourists. Only 1,600 people can visit Cala Sisine
while Santa Maria Navarrese only permits 1,300 euros.
(§7º)Fewer still are able to visit Cala Mariolu, with only
550 people allowed in per day and each having to pay a
1 euro fee. Elsewhere, Pelosa Beach has banned towels
and asked visitors to instead bring mats which gather
less sand. Anyone visiting will have to pay 3.50 euros.
(§8º)Meanwhile, tourists wanting to visit the beaches of
Cala Coticcio and Cala Brigantina in the archipelago of
La Maddalena will have to pay 3 euros per person for
access each day after new rules were brought in. The
archipelago itself is a national park and only accessible
with a guide, which will cost 25 euros for five hours.
(§9º)And anyone caught visiting the archipelago without a
guide could face prosecution. Just 60 people will be
permitted on each beach per day, as the local authorities
look at ways to protect the sites from the impact of
tourism.
(§10º)Slots must be booked in advance by contacting a
local guide but it is hoped that an app will be launched
soon. Here are several other pink beaches
holidaymakers can visit across Europe - and one's in the
UK. And a beach in the Canary Islands even has sand
that looks like popcorn, due to the shape of the coral.
itssfnneed
w.thesun.co.uk/travel/22667535/pink-beach-italy-bundelli-tourists-fined/
Identify the grammatical class of the word "unauthorised"
(§3º) in the text:
Ano: 2023
Banca:
CESGRANRIO
Órgão:
Banco do Brasil
Prova:
CESGRANRIO - 2023 - Banco do Brasil - Agente Comercial - Prova C |
Q2217913
Inglês
Texto associado
Available at: https://www.forbes.com/advisor/personal-finance/
how-to-teach-your-kids-good-money-habits/ Retrieved on: Jan.
2, 2023. Adapted.
In the segment of paragraph 2, “Saving teaches goalsetting and planning. It emphasizes being prepared, and
it builds security and independence.” the word “it” is a
reference to
Conheça nossos planos